168 related articles for article (PubMed ID: 22781071)
21. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
22. Associations of MGMT promoter hypermethylation with squamous intraepithelial lesion and cervical carcinoma: A meta-analysis.
Huang J; Luo JY; Tan HZ
PLoS One; 2019; 14(10):e0222772. PubMed ID: 31574102
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of epigenetic inactivation of p16, p15, MGMT and DAPK genes in follicular lymphoma.
Krajnović M; Radojković M; Davidović R; Dimitrijević B; Krtolica K
Med Oncol; 2013 Mar; 30(1):441. PubMed ID: 23275143
[TBL] [Abstract][Full Text] [Related]
24. [Promoter methylation of DAPK gene in cervical carcinoma].
Zhao XL; Meng ZY; Qiao YH; Zhang HL
Ai Zheng; 2008 Sep; 27(9):919-23. PubMed ID: 18799028
[TBL] [Abstract][Full Text] [Related]
25. Detecting methylation patterns of p16, MGMT, DAPK and E-cadherin genes in multiple myeloma patients.
Yuregir OO; Yurtcu E; Kizilkilic E; Kocer NE; Ozdogu H; Sahin FI
Int J Lab Hematol; 2010 Apr; 32(2):142-9. PubMed ID: 19302404
[TBL] [Abstract][Full Text] [Related]
26. Detection of hypermethylated genes in women with and without cervical neoplasia.
Feng Q; Balasubramanian A; Hawes SE; Toure P; Sow PS; Dem A; Dembele B; Critchlow CW; Xi L; Lu H; McIntosh MW; Young AM; Kiviat NB
J Natl Cancer Inst; 2005 Feb; 97(4):273-82. PubMed ID: 15713962
[TBL] [Abstract][Full Text] [Related]
27. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
[TBL] [Abstract][Full Text] [Related]
28. Aberrant promoter methylation in pleural fluid DNA for diagnosis of malignant pleural effusion.
Katayama H; Hiraki A; Aoe K; Fujiwara K; Matsuo K; Maeda T; Murakami T; Toyooka S; Sugi K; Ueoka H; Tanimoto M
Int J Cancer; 2007 May; 120(10):2191-5. PubMed ID: 17285579
[TBL] [Abstract][Full Text] [Related]
29. Methylation of the hsa-miR-124, SOX1, TERT, and LMX1A genes as biomarkers for precursor lesions in cervical cancer.
Rogeri CD; Silveira HCS; Causin RL; Villa LL; Stein MD; de Carvalho AC; Arantes LMRB; Scapulatempo-Neto C; Possati-Resende JC; Antoniazzi M; Longatto-Filho A; Fregnani JHTG
Gynecol Oncol; 2018 Sep; 150(3):545-551. PubMed ID: 29960712
[TBL] [Abstract][Full Text] [Related]
30. Methylation status of nine tumor suppressor genes in multiple myeloma.
Braggio E; Maiolino A; Gouveia ME; Magalhães R; Souto Filho JT; Garnica M; Nucci M; Renault IZ
Int J Hematol; 2010 Jan; 91(1):87-96. PubMed ID: 20037750
[TBL] [Abstract][Full Text] [Related]
31. Identification of methylation markers for the prediction of nodal metastasis in oral and oropharyngeal squamous cell carcinoma.
Melchers LJ; Clausen MJ; Mastik MF; Slagter-Menkema L; van der Wal JE; Wisman GB; Roodenburg JL; Schuuring E
Epigenetics; 2015; 10(9):850-60. PubMed ID: 26213212
[TBL] [Abstract][Full Text] [Related]
32. DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma.
Zhang J; Martins CR; Fansler ZB; Roemer KL; Kincaid EA; Gustafson KS; Heitjan DF; Clark DP
Clin Cancer Res; 2005 Sep; 11(18):6544-9. PubMed ID: 16166431
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of candidate methylation markers to detect cervical neoplasia.
Shivapurkar N; Sherman ME; Stastny V; Echebiri C; Rader JS; Nayar R; Bonfiglio TA; Gazdar AF; Wang SS
Gynecol Oncol; 2007 Dec; 107(3):549-53. PubMed ID: 17894941
[TBL] [Abstract][Full Text] [Related]
34. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response.
Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B
Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275
[TBL] [Abstract][Full Text] [Related]
35. Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma.
Kontic M; Stojsic J; Jovanovic D; Bunjevacki V; Ognjanovic S; Kuriger J; Puumala S; Nelson HH
Clin Lung Cancer; 2012 Jul; 13(4):297-303. PubMed ID: 22169480
[TBL] [Abstract][Full Text] [Related]
36. Similar DNA methylation pattern in lung tumours from smokers and never-smokers with second-hand tobacco smoke exposure.
Scesnaite A; Jarmalaite S; Mutanen P; Anttila S; Nyberg F; Benhamou S; Boffetta P; Husgafvel-Pursiainen K
Mutagenesis; 2012 Jul; 27(4):423-9. PubMed ID: 22217548
[TBL] [Abstract][Full Text] [Related]
37. RASSF1A promoter methylation was associated with the development, progression and metastasis of cervical carcinoma: a meta-analysis with trial sequential analysis.
Zheng F; Yu H
Arch Gynecol Obstet; 2018 Feb; 297(2):467-477. PubMed ID: 29288321
[TBL] [Abstract][Full Text] [Related]
38. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
[TBL] [Abstract][Full Text] [Related]
39. Association of aberrant DNA methylation with clinicopathological features in breast cancer.
Tserga A; Michalopoulos NV; Levidou G; Korkolopoulou P; Zografos G; Patsouris E; Saetta AA
Oncol Rep; 2012 May; 27(5):1630-8. PubMed ID: 22159596
[TBL] [Abstract][Full Text] [Related]
40. Aberrant gene-specific DNA methylation signature analysis in cervical cancer.
Bhat S; Kabekkodu SP; Varghese VK; Chakrabarty S; Mallya SP; Rotti H; Pandey D; Kushtagi P; Satyamoorthy K
Tumour Biol; 2017 Mar; 39(3):1010428317694573. PubMed ID: 28351298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
